Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.

de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, D'Amico R, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Gribaudo S, Provencher D, Hanzen C, Kruitwagen RF, Smit VTHBM, Singh N, Do V, Lissoni A, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC Study Group.

Lancet Oncol. 2019 Sep;20(9):1273-1285. doi: 10.1016/S1470-2045(19)30395-X. Epub 2019 Jul 22. Erratum in: Lancet Oncol. 2019 Sep;20(9):e468.

2.

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy.

Wortman BG, Creutzberg CL, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, van der Steen-Banasik EM, Mens JWM, Slot A, Kroese MCS, van Triest B, Nijman HW, Stelloo E, Bosse T, de Boer SM, van Putten WLJ, Smit VTHBM, Nout RA; PORTEC Study Group.

Br J Cancer. 2018 Oct;119(9):1067-1074. doi: 10.1038/s41416-018-0310-8. Epub 2018 Oct 25.

3.

Adjuvant therapy for high-risk endometrial cancer: recent evidence and future directions.

De Boer SM, Nout RA, Bosse T, Creutzberg CL.

Expert Rev Anticancer Ther. 2019 Jan;19(1):51-60. doi: 10.1080/14737140.2019.1531708. Epub 2018 Oct 24. Review.

PMID:
30295094
4.

Investigators' response.

Nout RA, Powell ME, de Boer SM, Creutzberg CL.

Lancet Oncol. 2018 May;19(5):602. doi: 10.1016/S1470-2045(18)30279-1. No abstract available.

PMID:
29726377
5.

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.

de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LCHW, Smit VTHBM, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC study group.

Lancet Oncol. 2018 Mar;19(3):295-309. doi: 10.1016/S1470-2045(18)30079-2. Epub 2018 Feb 12. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.

6.

Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer.

de Boer SM, Wortman BG, Bosse T, Powell ME, Singh N, Hollema H, Wilson G, Chowdhury MN, Mileshkin L, Pyman J, Katsaros D, Carinelli S, Fyles A, McLachlin CM, Haie-Meder C, Duvillard P, Nout RA, Verhoeven-Adema KW, Putter H, Creutzberg CL, Smit VTHBM; for PORTEC Study Group.

Ann Oncol. 2018 Feb 1;29(2):424-430. doi: 10.1093/annonc/mdx753.

7.

A glycerophospholipid-specific pocket in the RVFV class II fusion protein drives target membrane insertion.

Guardado-Calvo P, Atkovska K, Jeffers SA, Grau N, Backovic M, Pérez-Vargas J, de Boer SM, Tortorici MA, Pehau-Arnaudet G, Lepault J, England P, Rottier PJ, Bosch BJ, Hub JS, Rey FA.

Science. 2017 Nov 3;358(6363):663-667. doi: 10.1126/science.aal2712.

PMID:
29097548
8.

Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.

de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Kitchener HC, Nijman HW, Kruitwagen RF, Nout RA, Verhoeven-Adema KW, Smit VT, Putter H, Creutzberg CL; PORTEC study group.

Lancet Oncol. 2016 Aug;17(8):1114-1126. doi: 10.1016/S1470-2045(16)30120-6. Epub 2016 Jul 7.

9.

Screening of a Library of FDA-Approved Drugs Identifies Several Enterovirus Replication Inhibitors That Target Viral Protein 2C.

Ulferts R, de Boer SM, van der Linden L, Bauer L, Lyoo HR, Maté MJ, Lichière J, Canard B, Lelieveld D, Omta W, Egan D, Coutard B, van Kuppeveld FJ.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2627-38. doi: 10.1128/AAC.02182-15. Print 2016 May.

10.

Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial.

de Boer SM, Nout RA, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Stenfert Kroese MC, Oerlemans S, Putter H, Verhoeven-Adema KW, Nijman HW, Creutzberg CL.

Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):797-809. doi: 10.1016/j.ijrobp.2015.08.023. Epub 2015 Aug 18.

11.

New DIVA vaccine for the protection of poultry against H5 highly pathogenic avian influenza viruses irrespective of the N-subtype.

Peeters B, de Boer SM, Tjeerdsma G, Moormann R, Koch G.

Vaccine. 2012 Nov 19;30(49):7078-83. doi: 10.1016/j.vaccine.2012.09.050. Epub 2012 Oct 2.

PMID:
23036502
12.

Acid-activated structural reorganization of the Rift Valley fever virus Gc fusion protein.

de Boer SM, Kortekaas J, Spel L, Rottier PJ, Moormann RJ, Bosch BJ.

J Virol. 2012 Dec;86(24):13642-52. doi: 10.1128/JVI.01973-12. Epub 2012 Oct 3.

13.

Heparan sulfate facilitates Rift Valley fever virus entry into the cell.

de Boer SM, Kortekaas J, de Haan CA, Rottier PJ, Moormann RJ, Bosch BJ.

J Virol. 2012 Dec;86(24):13767-71. doi: 10.1128/JVI.01364-12. Epub 2012 Sep 26.

14.

Non-invasive computed tomography coronary angiography as a gatekeeper for invasive coronary angiography.

de Graaf FR, van Velzen JE, de Boer SM, van Werkhoven JM, Kroft LJ, de Roos A, Sieders A, de Grooth GJ, Jukema JW, Schuijf JD, Bax JJ, Schalij MJ, van der Wall EE.

Int J Cardiovasc Imaging. 2013 Jan;29(1):221-8. doi: 10.1007/s10554-012-0059-8. Epub 2012 May 11.

15.

Bead-based suspension array for simultaneous detection of antibodies against the Rift Valley fever virus nucleocapsid and Gn glycoprotein.

van der Wal FJ, Achterberg RP, de Boer SM, Boshra H, Brun A, Maassen CB, Kortekaas J.

J Virol Methods. 2012 Aug;183(2):99-105. doi: 10.1016/j.jviromet.2012.03.008. Epub 2012 Mar 16.

PMID:
22449758
16.

Efficacy of three candidate Rift Valley fever vaccines in sheep.

Kortekaas J, Antonis AF, Kant J, Vloet RP, Vogel A, Oreshkova N, de Boer SM, Bosch BJ, Moormann RJ.

Vaccine. 2012 May 14;30(23):3423-9. doi: 10.1016/j.vaccine.2012.03.027. Epub 2012 Mar 24.

PMID:
22449427
17.

Impact of clinical presentation and pretest likelihood on the relation between calcium score and computed tomographic coronary angiography.

van Werkhoven JM, de Boer SM, Schuijf JD, Cademartiri F, Maffei E, Jukema JW, Boogers MJ, Kroft LJ, de Roos A, Bax JJ.

Am J Cardiol. 2010 Dec 15;106(12):1675-9. doi: 10.1016/j.amjcard.2010.08.014. Epub 2010 Nov 4.

PMID:
21055714
18.

Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector.

Kortekaas J, de Boer SM, Kant J, Vloet RP, Antonis AF, Moormann RJ.

Vaccine. 2010 Jun 17;28(27):4394-401. doi: 10.1016/j.vaccine.2010.04.048. Epub 2010 Apr 29.

PMID:
20434545
19.

Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus.

Kortekaas J, Dekker A, de Boer SM, Weerdmeester K, Vloet RP, de Wit AA, Peeters BP, Moormann RJ.

Vaccine. 2010 Mar 8;28(11):2271-6. doi: 10.1016/j.vaccine.2010.01.001. Epub 2010 Jan 14.

PMID:
20079874
20.

Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge.

de Boer SM, Kortekaas J, Antonis AF, Kant J, van Oploo JL, Rottier PJ, Moormann RJ, Bosch BJ.

Vaccine. 2010 Mar 8;28(11):2330-9. doi: 10.1016/j.vaccine.2009.12.062. Epub 2010 Jan 5.

PMID:
20056185
21.

A controlled trial of senna preparations and other laxatives used for bowel cleansing prior to radiological examination.

Brouwers JR, van Ouwerkerk WP, de Boer SM, Thoman L.

Pharmacology. 1980;20 Suppl 1:58-64.

PMID:
6990426
22.

[Skull and tooth abnormalities in a patient with osteopathia striata].

De Boer SM, Van Gool AV.

Ned Tijdschr Geneeskd. 1974 Sep 7;118(36):1373-80. Dutch. No abstract available.

PMID:
4410894

Supplemental Content

Loading ...
Support Center